Introduction {#s1}
============

The differentiation of muscle precursor cells into contractile skeletal muscle fibers is necessary for normal muscle development and regeneration. Vertebrate skeletal muscles consist of a range of fiber types, from slow-twitch fibers needed for low-intensity, sustained aerobic activity, to fast-twitch fibers suited for short bursts of intense, anaerobic activity ([@b48]). Muscle fiber types are operationally defined by the expression of myosin heavy chain (MyHC) genes ([@b35]; [@b28]). In mammals, 11 MyHC genes contribute to skeletal muscle fiber heterogeneity and functional flexibility ([@b36]). However, muscle fiber types are distinguished not just by MyHC expression but by the expression of other sarcomeric proteins, most of which also exist as multiple isoforms, as well as by isoforms of intracellular calcium signaling components and levels of metabolic enzymes ([@b35]; [@b28]; [@b36]). Thus, it is the coordinated expression of fiber-type-specific gene expression programs that gives each fiber type its unique contractile and metabolic properties.

Ultimately, the expression of skeletal muscle differentiation genes, including those encoding the MyHCs and other sarcomeric proteins, is controlled by the family of myogenic basic helix--loop--helix (bHLH) transcription factors: Myf5, Myod, Myf6 and Myog ([@b6]; [@b40]). In particular, Myod can directly bind to the promoters and activate the expression of both slow and fast MyHCs ([@b9]). How do factors like Myod activate their transcriptional targets in a temporally and spatially controlled manner to drive cell-type-specific, or fiber-type-specific, differentiation? Our work has shown that Pbx TALE-class homeodomain proteins function as cofactors for Myod and regulate a subset of Myod target genes, in particular to promote fast-muscle-specific differentiation ([@b3]; [@b23]). We have shown that Pbx proteins bind with Myod on the promoters of a subset of Myod target genes, including *Myog* and the fast muscle gene *mylpfa*, and that Pbx proteins are required for Myod to activate *myog* and *mylpfa* expression and the fast-muscle-specific differentiation program in zebrafish embryos ([@b3]; [@b23]). Our specific hypothesis is that Pbx homeodomain proteins function as pioneer transcription factors to direct Myod to a subset of its transcriptional targets, in particular fast muscle differentiation genes, thereby regulating the competence of muscle precursor cells to differentiate into a specific fiber type.

Pioneer factors are transcription factors that have the ability to access and bind DNA in repressive chromatin and that bind prior to gene activation and prior to the presence of other transcription factors ([@b51]). Pbx proteins have recently been shown to function as pioneer factors in breast cancer cells, where PBX1 binds prior to, and is required for, Estrogen Receptor binding ([@b22]). Supporting the role of Pbx proteins as pioneer factors in skeletal muscle differentiation, Pbx proteins can bind silent Myod target gene promoters prior to Myod binding and muscle differentiation ([@b3]). Pioneer factors can function in passive roles, in which their presence reduces the number of additional transcription factor binding events needed, or in more active roles, in which they facilitate chromatin opening that is necessary before other factors can bind ([@b51]). Whether Pbx proteins act in passive or active roles as pioneer factors is not known.

To address how Pbx proteins function in muscle fiber-type differentiation, here we use zebrafish to examine how Pbx interacts with another fiber-type regulator, Prdm1a. In zebrafish, slow-twitch fibers derive from the adaxial cells, the most medial paraxial mesoderm cells, whereas more lateral somitic cells will give rise to fast-twitch fibers ([@b14]). Adaxial cells express the transcriptional repressor Prdm1a/Blimp1, which is both necessary and sufficient for slow MyHC expression and specification of slow twitch fiber identity ([@b1]). In zebrafish, many fast muscle genes are initially transiently co-expressed with slow muscle genes in the adaxial cells before differentiation is completed ([@b5]; [@b8]). In *prdm1a* mutant zebrafish embryos, the expression of *smyhc1* and other slow muscle genes is reduced in the adaxial cells, while fast muscle genes show increased and premature expression in the adaxial cells ([@b32]; [@b1]; [@b43]; [@b20]). Pbx and Prdm1a thus have opposite requirements for fast muscle differentiation in zebrafish. Here we combine loss of function of both Pbx proteins and Prdm1a to test the requirements for Pbx in promoting fast muscle differentiation. We use RNA-seq to identify subsets of the fast-muscle program that are either co-regulated by Pbx and Prdm1 or independently regulated by these factors. We find that in embryos lacking both Pbx and Prdm1a, the levels of expression of many fast muscle genes are approximately wild type or are increased relative to wild type, suggesting that, for a subset of the fast muscle program, a major role for Pbx is to counter the repressive action of Prdm1a. However, certain fast muscle genes require Pbx but are not regulated by Prdm1a. Thus, our findings reveal that subsets of the fast muscle program are differentially regulated by Pbx and Prdm1a. Our findings provide an example of how Pbx pioneer factors act in a balance with other transcriptional regulators to direct a specific cellular differentiation pathway.

Results {#s2}
=======

*prdm1a* is epistatic to *pbx2/4* for fast muscle gene expression in adaxial cells {#s2a}
----------------------------------------------------------------------------------

One advantage of using zebrafish to study Pbx functions in early muscle differentiation is that we have the ability to remove all Pbx function by using morpholinos to knock down maternal and zygotic expression of both *pbx2* and *pbx4* (*pbx2/4*), the two *pbx* genes expressed in young zebrafish embryos ([@b45]; [@b23]). *pbx2/4* and *prdm1a* have opposite requirements for fast muscle gene expression in zebrafish: in the absence of Pbx2/4, fast muscle gene expression in both adaxial cells and lateral cells is reduced and delayed, whereas in the absence of Prdm1a, fast muscle gene expression occurs prematurely and at increased levels in adaxial cells ([@b23]; [@b32]; [@b1]; [@b43]; [@b20]). We wanted to combine loss of function of both *pbx2/4* and *prdm1a* to test the requirements for Pbx in promoting fast muscle gene expression. We reasoned that if Pbx proteins, as pioneer factors, play a necessary role in assembling factors to drive fast-muscle gene expression, then expression of fast muscle genes should be reduced and delayed in *pbx2/4*-MO;*prdm1a−/−* embryos, as in *pbx2/4*-MO embryos. Alternatively, if, in the adaxial cells, Pbx proteins are primarily needed to overcome the repressive actions of Prdm1a, then expression of fast muscle genes should appear at increased levels in *pbx2/4*-MO;*prdm1a−/−* embryos, as in *prdm1a−/−* embryos. We first confirmed that *pbx2/4* and *prdm1a* are not required for each other\'s expression ([Fig. 1](#f01){ref-type="fig"}). We then examined the expression of three target genes in *pbx2/4*-MO;*prdm1a−/−* double loss-of-function embryos: *mylpfa*, *myhz1.3*, and *myog* ([Fig. 2](#f02){ref-type="fig"}). *mylpfa* and *myhz1.3* encode fast muscle sarcomere proteins whose expression is positively, and, in the case of *mylpfa*, directly, regulated by Pbx2/4 and directly repressed by Prdm1a ([Fig. 2A--D](#f02){ref-type="fig"}) ([@b23]; [@b43]; [@b20]). *myog*, which encodes a muscle regulatory transcription factor, is directly and positively regulated by Pbx and shows upregulation in the adaxial cells of *prdm1a−/−* embryos, indicating that *myog* is normally repressed by Prdm1a ([Fig. 2E,F](#f02){ref-type="fig"}) ([@b23]; [@b24]). In *pbx2/4*-MO;*prdm1a−/−* embryos, we find upregulation of *mylpfa*, *myhz1.3*, and *myog* in the adaxial cells relative to the controls ([Fig. 2A,C,E](#f02){ref-type="fig"}), resembling the phenotype of *prdm1a−/−* embryos. Using real-time PCR (qRT-PCR) to quantitatively examine these markers, we find that *mylpfa* and *myhz1.3* expression are strongly upregulated in *pbx2/4*-MO;*prdm1a−/−* embryos relative to both control and *pbx2/4*-MO embryos, although not quite to the levels seen in *prdm1a−/−* embryos ([Fig. 2B,D](#f02){ref-type="fig"}). For *myog*, we find that the level of expression in *pbx2/4*-MO;*prdm1a−/−* embryos is close to the control level ([Fig. 2F](#f02){ref-type="fig"}), and, based on the in situ pattern, seems to represent an upregulation of *myog* in the adaxial cells of *pbx2/4*-MO;*prdm1a−/−* embryos but absence of the more lateral Pbx-dependent expression ([Fig. 2E](#f02){ref-type="fig"}). These results show that expression of *mylpfa*, *myhz1.3*, and *myog* within the *prdm1a*-expressing adaxial cells is upregulated in *pbx2/4*-MO;*prdm1a−/−* embryos, resembling the *prdm1a−/−* phenotype.

![*pbx2/4* and *prdm1a* are not required for each other\'s expression.\
(**A**,**B**) RNA in situ expression of *prdm1a* and *krox-20* in (A) control and (B) *pbx2/4*-MO embryos. *prdm1a* expression in the adaxial cells along the axis of the embryo is maintained, while *krox-20* expression is lost, in *pbx2/4*-MO embryos. Arrowheads point to adaxial cells, and r3 and r5 indicate *krox-20* expression in hindbrain rhombomeres. (**C**,**D**) Anti-Pbx (red) and DAPI (blue) staining, along with merged images, in (C) control and (D) *prdm1a−/−* embryos. Pbx expression is maintained in *prdm1a−/−* embryos. All embryos are shown in dorsal view, anterior towards the left. Scale bars: (A) 50 µm, (C) 10 µm.](bio-02-06-546-f01){#f01}

![Expression of Pbx and Prdm1a target genes in *pbx2/4*-MO;*prdm1a−/−* embryos.\
(**A**,**C**,**E**) RNA in situ expression of (A) *mylpfa* and *krox-20*, (C) *myhz1.3* and *krox-20*, and (E) *myog* and *krox-20* in green, *smyhc1* in red, and merged images in control, *pbx2/4*-MO, *prdm1a−/−*, and *pbx2/4*-MO;*prdm1a−/−* embryos. *krox-20* expression is included as a control for the *pbx2/4*-MO knockdown ([@b23]). r3 and r5 indicate *krox-20* expression in hindbrain rhombomeres. *smyhc1* is downregulated in *prdm1a−/−* embryos ([@b15]; [@b43]). (A,C) embryos are at 14 somites, (E) embryos are at 10 somites. All embryos are shown in dorsal view, anterior towards the left. Somites were counted in all embryos shown to confirm consistent staging. (**B**,**D**,**F**) Graphs of real-time RT-PCR (qRT-PCR) expression levels for (B) *mylpfa*, (D) *myhz1.3*, and (F) *myog*. Expression levels were normalized to *odc1* expression. Error bars represent standard deviation. Somite stages (14 s, 10 s) are shown. Scale bar: 50 µm.](bio-02-06-546-f02){#f02}

To more thoroughly examine the Pbx- and Prdm1a-regulated expression of *mylpfa*, we examined higher magnification confocal images. In control embryos at 14s, *mylpfa* is expressed in both lateral cells and in adaxial cells, where its expression coincides with the slow muscle gene *smyhc1* ([Fig. 3A](#f03){ref-type="fig"}) ([@b8]). In *pbx2/4*-MO embryos, both adaxial and lateral expression domains are lost ([Fig. 3B](#f03){ref-type="fig"}), showing that Pbx is needed to promote *mylpfa* expression in both adaxial and lateral cells. In *prdm1a−/−* embryos, adaxial and lateral expression of *mylpfa* are present ([Fig. 3C](#f03){ref-type="fig"}). Critically, in *pbx2/4*-MO;*prdm1a−/−* embryos, adaxial expression of *mylpfa* is maintained, as in *prdm1−/−* embryos, whereas the lateral domain is reduced or absent as in *pbx2/4*-MO embryos ([Fig. 3D](#f03){ref-type="fig"}). Taken together, the results in [Figs 2](#f02){ref-type="fig"} and [3](#f03){ref-type="fig"} show that *prdm1a* is epistatic to *pbx2/4* for fast muscle gene expression in adaxial cells, revealing that *pbx2/4* functions as a genetic suppressor of *prdm1a*.

![Adaxial cell expression of *mylpfa* is absent in *pbx2/4*-MO embryos but present in *pbx2/4*-MO;*prdm1a−/−* embryos.\
RNA in situ expression of *mylpfa* (green) and *smyhc1* (red) in (**A**) control, (**B**) *pbx2/4*-MO, (**C**) *prdm1a−/−*, and (**D**) *pbx2/4*-MO;*prdm1a−/−* embryos. Embryos are 14 somites stage, shown in dorsal view, anterior towards the left. Somite numbers 2--7 are shown for each embryo. Yellow lines indicate where optical sections are taken through the x and y planes (lower and right panels, respectively, each image). Dorsal--ventral (D--V) axes (z axis in xy view) are indicated. Arrowheads point to lateral domain of *mylpfa* expression, absent or reduced in *pbx2/4*-MO and *pbx2/4*-MO;*prdm1a−/−* (asterisk) embryos. *smyhc1*-overlapping *mylpfa* expression in adaxial cells is present in *pbx2/4*-MO;*prdm1a−/−* embryos. Scale bar: 50 µm.](bio-02-06-546-f03){#f03}

RNA-seq approach to identify Pbx2/4- and Prdm1a-regulated genes: comparison with previous expression array studies {#s2b}
------------------------------------------------------------------------------------------------------------------

We next wanted to ask whether *prdm1a* functions epistatically to *pbx2/4* broadly across the fast-muscle gene expression program or only at subsets of fast muscle genes. We confirmed that Pbx2/4 and Prdm1a could independently regulate known dependent genes by showing that *krox-20* is strongly downregulated in *pbx2/4*-MO and *pbx2/4*-MO;*prdm1a−/−*, but not in *prdm1a−/−*, embryos, and that *smyhc1* is strongly downregulated in *prdm1a−/−* and *pbx2/4*-MO;*prdm1a−/−*, but not in *pbx2/4*-MO, embryos ([Fig. 2A](#f02){ref-type="fig"}, [Fig. 4](#f04){ref-type="fig"}) ([@b45]; [@b15]; [@b43]). To globally assess which subsets of the fast muscle program are regulated by both Pbx2/4 and Prdm1a versus those that are regulated by either Pbx or Prdm1a, we used high-throughput sequencing of mRNA libraries (RNA-seq). We generated libraries for control *prdm1a+/+* embryos, *pbx2/4*-MO embryos, *prdm1a−/−* embryos and *pbx2/4*-MO;*prdm1a−/−* embryos in triplicate at the 10 somite (s) stage (see [Materials and Methods](#s4){ref-type="sec"}). We chose this stage because it is when early skeletal muscle differentiation initiates in zebrafish and we wanted to assess the earliest muscle requirements for Pbx2/4 and Prdm1a. We also chose this stage in order to compare with previous expression array analyses that we performed on 10 s control and *pbx2/4*-MO embryos ([@b23]; [@b24]). Because we could not reliably sort live *prdm1a* mutant embryos from their wild-type siblings at 10 s, we developed a technique to genotype RNA samples from individual embryos (see [Materials and Methods](#s4){ref-type="sec"}). We pooled equivalent-genotype RNA samples for our RNA-seq libraries (see [Materials and Methods](#s4){ref-type="sec"}).

![Pbx2/4 and Prdm1a independently regulate genes.\
Graphs of qRT-PCR expression levels for (**A**,**B**) *krox-20* and (**C**,**D**) *smyhc1*. Expression levels were normalized to *odc1* expression. Error bars represent standard deviation. Somite stages (10 s, 14 s) are shown.](bio-02-06-546-f04){#f04}

As an initial assessment of the RNA-seq data, we examined results from *pbx2/4*-MO and *prdm1a−/−*, each relative to control. Using the cut-offs of \>1.5-fold change and significance of *P*\<0.05, we identified 637 genes that are downregulated in *pbx2/4*-MO embryos compared to controls ([supplementary material Table S1](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)). This group of 637 genes includes the Pbx targets *mylpfa*, *myog*, and *krox-20* and includes 72/111 (65%) of the genes that we had previously identified with expression arrays as downregulated in *pbx2/4*-MO 10 s embryos, including 10/12 genes that we had validated by in situ hybridization ([supplementary material Table S1](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)) ([@b23]). Additionally, this group of 637 genes includes 6 genes that we previously identified as downregulated in *pbx2/4*-MO embryos with expression arrays at 18 s, but not with arrays at 10 s, including *mylpfa* ([supplementary material Table S1](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)) ([@b23]). Thus, although it is not clear why our RNA-seq analysis did not identify all of the genes previously identified with the expression arrays at 10 s, overall it appears that the RNA-seq analysis is more sensitive than our previous expression array analysis, because we identified genes at 10 s from RNA-seq that the expression arrays only picked up at 18 s. We also identified 142 genes that are upregulated in *prdm1a−/−* embryos compared to controls ([supplementary material Table S2](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)). This group of 142 genes includes the Prdm1a direct targets *mylpfa* and *myhz2* and known *prdm1a*-regulated genes *agr2*, *myl1*, and *myhz1.3* ([supplementary material Table S2](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)) ([@b43]; [@b16]; [@b8]). Altogether, our initial assessment shows that our RNA-seq analysis has identified Pbx2/4- and Prdm1-dependent genes.

RNA-seq analysis identifies subsets of the fast muscle program that are differentially regulated by Pbx2/4 and Prdm1a {#s2c}
---------------------------------------------------------------------------------------------------------------------

Because Pbx2/4 and Prdm1a have both been shown to broadly regulate the fast muscle gene expression program ([@b23]; [@b43]), we used the RNA-seq data to ask if Pbx2/4 and Prdm1a each regulate completely overlapping sets of fast muscle genes. We compared the genes downregulated in *pbx2/4*-MO embryos ([supplementary material Table S1](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)) with the genes upregulated in *prdm1a−/−* embryos ([supplementary material Table S2](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)). At this early muscle differentiation stage, we find 12 genes overlapping between these two groups ([Fig. 5A,B](#f05){ref-type="fig"}). The overlapping genes include fast muscle genes *atp2a1*, *myl1* and *mylpfa* ([Fig. 5B](#f05){ref-type="fig"}). We then examined the gene lists from [supplementary material Tables S1 and S2](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1) and found additional fast muscle genes in either the downregulated-in-*pbx2/4*-MO set or the upregulated-in-*prdm1a−/−* set ([Fig. 5B](#f05){ref-type="fig"}). These results show that *pbx2/4* and *prdm1a* regulate overlapping as well as distinct sets of fast muscle differentiation genes.

![*pbx2/4* and *prdm1a* regulate overlapping and distinct subsets of fast muscle differentiation genes, identified through RNA-seq.\
(**A**) Venn diagram identifying the intersection (12 genes) of the set of genes downregulated in *pbx2/4*-MO embryos (*pbx2/4*-MO\<control, [supplementary material Table S1](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)) with the set of genes upregulated in *prdm1a−/−* embryos (*prdm1a−/−*\>control, [supplementary material Table S2](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)). (**B**) List of the 12 genes identified in A. Also shown are fast muscle genes regulated by Pbx2/4, independently of Prdm1a, and those regulated by Prdm1a, independently of Pbx2/4, as identified from [supplementary material Tables S1 and S2](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1). The asterisk refers to fast myosin heavy chain genes that were not identified as Pbx2/4-dependent through RNA-seq, but that are known through additional validation to be Pbx2/4-dependent (see [Fig. 2](#f02){ref-type="fig"} and Discussion).](bio-02-06-546-f05){#f05}

We next examined the RNA-seq results for the target genes analyzed in [Fig. 2](#f02){ref-type="fig"}, using the Integrative Genome Viewer ([@b31]) to visualize the data. As expected from our previous in situs and qRT-PCR, *mylpfa* and *myog* are downregulated in *pbx2/4*-MO embryos, upregulated in *prdm1a−/−* embryos, and remain upregulated in *pbx2/4*-MO;*prdm1a−/−* embryos ([Fig. 6A,B](#f06){ref-type="fig"}). For *myhz1.3*, expression is not detected in control and *pbx2/4*-MO embryos but is upregulated in *prdm1a−/−* and *pbx2/4*-MO;*prdm1a−/−* embryos ([Fig. 6C](#f06){ref-type="fig"}; see also Discussion). *krox-20* and *smyhc1* show expected expression patterns ([Fig. 6D,E](#f06){ref-type="fig"}). These results further validate our RNA-seq analysis.

![Visualization and validation of RNA-seq analysis.\
Mapping of RNA-seq reads as viewed in the Integrative Genomics Viewer for (**A**) *mylpfa*, (**B**) *myog*, (**C**) *myhz1.3*, (**D**) *krox-20*, and (**E**) *smyhc1*. Mapped reads are represented by grey histograms. Blue bars at the bottom of each panel represent annotated exons and UTRs (blue boxes) and introns (blue lines with arrowheads for orientation of transcript from 5′ to 3′) for each gene. For C, *myhz1.3* is not annotated but the genomic position is confirmed relative to neighboring annotated zebrafish myosin heavy chain genes and mammalian orthologues. For each gene, rows for reads from control, *pbx2/4*-MO, *prdm1a−/−*, and *pbx2/4*-MO;*prdm1a−/−* are shown, as in A.](bio-02-06-546-f06){#f06}

To globally determine whether *prdm1a* functions epistatically to *pbx2/4* broadly across the fast-muscle gene expression program, or only at subsets of fast muscle genes, we compared the data sets for genes downregulated in *pbx2/4*-MO embryos with three different data sets from *pbx2/4*-MO;*prdm1a−/−* embryos: 1, genes upregulated relative to control; 2, genes expressed at about control levels; and 3, genes downregulated relative to control. ([Fig. 7A--C](#f07){ref-type="fig"}). The overlap of Set 1 contains only four genes, but two of these are fast muscle myosin genes, *myl1* and *mylpfa* ([Fig. 7A](#f07){ref-type="fig"}; [supplementary material Table S3](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)). The overlap of Set 2 contains fast muscle differentiation genes, including *atp2a1*, a fast muscle SERCA Ca(2+)-ATPase ([@b49]), *ryr1b* ([@b17]), and also *myog* ([Fig. 7B](#f07){ref-type="fig"}; [supplementary material Table S3](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)). These analyses reveal that many fast muscle genes that are Pbx-dependent are indeed "rescued", relative to *pbx2/4*-MO levels, or upregulated in *pbx2/4*-MO;*prdm1a−/−* embryos. However, the overlap of Set 3 also contains fast muscle genes, such as *atp1a2a*, *myom1a* and *srl* ([Fig. 7C](#f07){ref-type="fig"}; [supplementary material Table S3](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1)). Thus, certain fast muscle genes that are Pbx-dependent are still downregulated in *pbx2/4*-MO;*prdm1a−/−* embryos. Taken together, our RNA-seq analysis reveals subsets of the fast muscle differentiation program that are differentially regulated by Pbx2/4 and Prdm1a.

![RNA-seq analysis identifies subsets of the fast muscle program that are differentially regulated by Pbx2/4 and Prdm1a.\
(**A--C**) Venn diagrams showing overlap of genes whose expression is downregulated in *pbx2/4*-MO embryos relative to control (green circles) compared to (A) genes that are upregulated in *pbx2/4*-MO;*prdm1−/−* embryos, (B) genes that are expressed at about control levels in *pbx2/4*-MO;*prdm1−/−* embryos, and (C) genes that are downregulated in *pbx2/4*-MO;*prdm1−/−* embryos. The number of genes in each overlap is shown in parentheses; genes are listed in [supplementary material Table S3](http://bio.biologists.org/lookup/suppl/doi:10.1242/bio.20133921/-/DC1).](bio-02-06-546-f07){#f07}

Validation of fast muscle genes differentially regulated by Pbx and Prdm1a {#s2d}
--------------------------------------------------------------------------

We next validated genes from each of these three sets of loci that are differentially regulated by Pbx and Prdm1a. For Set 1, we already demonstrated that *mylpfa* is upregulated in *pbx2/4*-MO;*prdm1a−/−* embryos ([Fig. 2](#f02){ref-type="fig"}), and we confirmed by both in situ and qRT-PCR that *myl1* is downregulated in *pbx2/4*-MO embryos, upregulated in *prdm1a−/−* embryos, and upregulated in *pbx2/4*-MO;*prdm1a−/−* embryos ([Fig. 8A,B](#f08){ref-type="fig"}). For Set 2, we already demonstrated that *myog* is expressed at about control levels in *pbx2/4*-MO;*prdm1a−/−* embryos ([Fig. 2](#f02){ref-type="fig"}), and we confirmed that *atp2a1* is downregulated in *pbx2/4*-MO embryos, upregulated in *prdm1a−/−* embryos, and expressed at about control levels in *pbx2/4*-MO;*prdm1a−/−* embryos ([Fig. 8C,D](#f08){ref-type="fig"}). Set 3 contains many neural genes, such as *krox-20*, that are known to be Pbx-dependent ([@b45]; [@b23]; [@b11]), and we already confirmed that *krox-20* is strongly downregulated in *pbx2/4*-MO and *pbx2/4*-MO;*prdm1a−/−* embryos but not affected in *prdm1a−/−* embryos ([Fig. 2](#f02){ref-type="fig"}, [Fig. 4](#f04){ref-type="fig"}). We have previously shown that *atp1a2a* is downregulated in *pbx2/4*-MO embryos ([@b23]). We also validated that the fast muscle gene *srl* is downregulated in *pbx2/4*-MO embryos, not affected in *prdm1a−/−* embryos, and remains downregulated in *pbx2/4*-MO;*prdm1a−/−* embryos ([Fig. 8D,E](#f08){ref-type="fig"}). This analysis demonstrates that certain fast muscle genes are Pbx-dependent but are not repressed by Prdm1a, confirming that subsets of the fast muscle program have different requirements for Pbx and Prdm1a.

![Validation of fast muscle genes differentially regulated by Pbx and Prdm1a.\
(**A**,**C**,**E**) RNA in situ expression of (A) *myl1* and *krox-20*, (C) *atp2a1* and *krox-20*, and (E) *srl* and *krox-20* in green, *smyhc1* in red, and merged images in control, *pbx2/4*-MO, *prdm1a−/−*, and *pbx2/4*-MO;*prdm1a−/−* embryos. *krox-20* expression is included as a control for the *pbx2/4*-MO knockdown ([@b23]). r3 and r5 indicate *krox-20* expression in hindbrain rhombomeres. *smyhc1* is downregulated in *prdm1a−/−* embryos ([@b15]; [@b43]). (A,C) embryos are at 14 somites, (E) embryos are at 18 somites. All embryos are shown in dorsal view, anterior towards the left. Somites were counted in all embryos shown to confirm consistent staging. (**B**,**D**,**F**) Graphs of real-time RT-PCR (qRT-PCR) expression levels for (B) *myl1*, (D) *atp2a1*, and (F) *srl*. Expression levels were normalized to *odc1* expression. Error bars represent standard deviation. Somite stage for qRT-PCR (14 s) is shown. Scale bar, 50 µm.](bio-02-06-546-f08){#f08}

Discussion {#s3}
==========

The coordinated expression of fiber-type-specific gene expression programs is necessary to give each fiber type its unique contractile properties. Pbx and Prdm1a proteins have previously been shown to have opposite requirements for fast muscle gene expression in zebrafish ([@b23]; [@b1]; [@b43]; [@b20]). Here we combined loss of function of both Pbx and Prdm1a to test the requirements for Pbx in promoting fast muscle differentiation. We used RNA-seq to identify subsets of the fast-muscle program that have different requirements for Pbx and Prdm1a. Our results reveal that there are multiple combinations of Pbx and Prdm1a inputs that regulate fast muscle gene expression ([Fig. 9](#f09){ref-type="fig"}). In lateral cells, fast muscle differentiation genes are positively regulated by Pbx and Myod, likely acting together, as has been shown for *mylpfa* ([@b23]) ([Fig. 9](#f09){ref-type="fig"}). In adaxial cells, *myl1* is repressed by Prdm1a but not regulated by Pbx, *srl* is positively regulated by Pbx and Myod but not regulated by Prdm1a, and *mylpfa* expression appears to be regulated through a balance of Pbx/Myod positive input and Prdm1a repression ([Fig. 9](#f09){ref-type="fig"} and references therein). Our results thus show that Pbx and Prdm1a transcription factors differentially regulate subsets of the fast skeletal muscle differentiation program in zebrafish.

![Multiple combinations of Pbx and Prdm1a inputs regulate fast muscle gene expression.\
Cartoons illustrating inputs for the expression of three fast muscle genes (**A**) *myl1*, (**B**) *mylpfa*, and (**C**) *srl*. Evidence for inputs comes from A ([@b8]; this work), B ([@b23]; [@b43]; [@b20]; this work), and C ([@b23]; this work). Inputs reflect genetic requirements, although, in the case of *mylpfa*, direct regulation by Pbx, Myod and Prdm1a has been demonstrated ([@b23]; [@b43]; [@b20]).](bio-02-06-546-f09){#f09}

Our results support the hypothesis that pioneer factors may function through different mechanisms depending on the target gene ([@b51]; [@b7]). For example, pioneer factors can play passive roles by reducing the number of additional transcription factor binding events needed for gene activation, or more active roles by opening up local chromatin to allow other factors to bind ([@b51]). Our findings suggest that, for a subset of fast muscle genes such as *mylpfa*, Pbx proteins are needed to repress the repressive activity of Prdm1a ([Fig. 9B](#f09){ref-type="fig"}), possibly by inhibiting Prdm1a binding or activity at fast muscle gene promoters. Pbx proteins have been shown to inhibit gene expression through interactions with transcriptional repressors ([@b34]; [@b2]; [@b11]), but activating gene expression by repressing a transcriptional repressor may entail a new mechanism for Pbx activity. Pbx proteins could take an active role in inhibiting Prdm1a, while promoting gene expression, by modifying chromatin states at fast muscle gene promoters through Pbx interactions with chromatin factors such as Brg1 or CBP ([@b13]; [@b11]). Other fast muscle genes, such as *srl*, are Prdm1a-independent but require Pbx for their activation. Further studies will be needed to understand the mechanisms by which Pbx proteins regulate different subsets of the fast muscle program, in particular how Pbx proteins repress the activity of Prdm1a.

We used an RNA-seq approach in order to globally assess which subsets of the fast muscle program are co-regulated by Pbx2/4 and Prdm1a versus those that are independently regulated. In general, we found that our RNA-seq approach was more sensitive in identifying differentially expressed genes than our previous expression array approach with *pbx2/4*-MO embryos ([@b23]). Our analysis at the 10-somite stage allowed us to assess the earliest muscle differentiation requirements for both Pbx2/4 and Prdm1a, but we were not able to assess the entire fast muscle program because many fast muscle genes, such as *tnnt*, are not activated until later developmental stages ([@b50]). Some myosin heavy chain genes are expressed early, but we found the fast myosin heavy chain genes to be difficult to analyze by RNA-seq because the sequences of the six genes are so similar that sequencing reads may not get assigned properly. For example, based on our in situ and qRT-PCR analyses, *myhz1.3* should have been identified in [Fig. 5](#f05){ref-type="fig"} as Pbx-dependent and in [Fig. 7](#f07){ref-type="fig"} in Class 1 (strong expression levels in *pbx2/4*-MO;*prdm1a−/−* embryos), but *myhz1.3* RNA-seq expression levels were so low in control embryos ([Fig. 6C](#f06){ref-type="fig"}) that *myhz1.3* was not identified in the Pbx-dependent set. Another gene that was not identified by our RNA-seq approach is *sox6*, a known Prdm1a-dependent gene ([@b43]). However, even though *sox6* is expressed within fast muscle precursors and is regulated by Prdm1a and Myod ([@b43]; [@b44]), *sox6* does not appear to be regulated by Pbx2/4 (L.M., unpublished observations). Even though these examples are caveats to our RNA-seq analysis, they help provide further evidence that Pbx2/4 and Prdm1a regulate shared as well as independent aspects of the fast muscle program.

Why is a balance of factors needed for fiber-type differentiation? Like zebrafish slow muscle precursor cells, embryonic mammalian and avian myocytes and myofibers initially co-express both slow- and fast-type isoforms of many muscle differentiation genes ([@b25]; [@b38]; [@b21]; [@b12]; [@b33]; [@b26]). How this mixed slow/fast phenotype resolves into slow-twitch and multiple types of fast-twitch fibers is not fully understood. Perhaps a balance of factors that activate and repress subsets of fiber-type differentiation programs allows for increased plasticity in generating a variety of fiber types.

One outstanding question is whether Pbx and Prdm1 proteins are required for mammalian muscle differentiation. Mouse cell culture studies support a pioneer factor role for Pbx proteins in mouse skeletal muscle differentiation ([@b3]; [@b13]), but direct requirements for Pbx proteins in mammalian skeletal muscle have not yet been tested. A recent analysis of the mouse *Prdm1* conditional knock-out in embryonic myogenic cells or myogenic precursor cells revealed normal onset of myogenesis and normal expression of fast and slow muscle differentiation genes in the absence of *Prdm1* ([@b42]). This study even addressed functional compensation by another Prdm1-like factor by showing that expression of a dominant-negative Prdm1 had no effect on early mouse fast or slow skeletal muscle development ([@b42]). If Prdm1 factors are not required in early mammalian skeletal muscle differentiation, it remains a possibility that a different factor with similar activity could act in a balance with Pbx proteins. In future studies it will be important to determine whether Pbx proteins and a Prdm or Prdm-like factor function to regulate mammalian skeletal muscle fiber-type differentiation.

The coordinated expression of contractile gene expression programs is critical not only for skeletal muscle differentiation but also for myocardial and smooth muscle differentiation. Pbx proteins are expressed in myocardial and vascular smooth muscle cells and are needed for proper development of the heart and cardiac outflow tract ([@b10]; [@b37]; [@b24]). It is possible that Pbx proteins will act in a balance with other transcription factors to promote subsets of myocardial and smooth muscle differentiation programs.

Materials and Methods {#s4}
=====================

Zebrafish husbandry {#s4a}
-------------------

All experiments involving live zebrafish (*Danio rerio*) were carried out in compliance with IACUC guidelines. Zebrafish were raised and staged as previously described ([@b47]). Time (hpf) refers to hours post-fertilization at 28.5°C. In some cases, embryos were raised for periods at room temperature, about 25°C. The wild-type stock used was AB. The *prdm1a^m805^* mutant line has been described and is likely a null allele ([@b16]). *prdm1a^m805^* genotyping primers, *prdm1adcapsF2* and *prdm1adcapsR2* are in [Table 1](#t01){ref-type="table"}. The genotyping PCR product is 238 base pairs. Digesting with XmnI yields a 204 base pair product from the mutant allele.

###### Primers used.

![](bio-02-06-546-t01)

Morpholino and mRNA injections {#s4b}
------------------------------

Morpholino injections were performed, and working concentrations were determined, as previously described ([@b23]). Morpholinos were used at the following working concentrations: *pbx2*-MO2, CCGTTGCCTGTGATGGGCTGCTGCG, 0.25 mg/ml; *pbx2*-MO3, GCTGCAACATCCTGAGCACTACATT, 0.5 mg/ml; *pbx2*-MO3 5-base mis-match control, GCTcCAAgATCCTcAcCAgTACATT, 0.5 mg/ml; *pbx4*-MO1, AATACTTTTGAGCCGAATCTCTCCG, 0.5 mg/ml; *pbx4*-MO2, CGCCGCAAACCAATGAAAGCGTGTT, 0.5 mg/ml; Standard control-MO, CCTCTTACCTCAGTTACAATTTATA, 1 mg/ml. *pbx2*-MO2, *pbx2*-MO3, *pbx4*-MO1 and *pbx4*-MO2 were combined to make the *pbx2/4*-MO combination (3 nl injected). Western analysis confirmed loss of Pbx2 and Pbx4 expression in *pbx2/4*-MO-treated embryos ([@b23]). Embryos that are knocked-down for Pbx2 and Pbx4 function show a developmental delay of about 2 somites during somitogenesis stages ([@b23]). We somite stage-matched sibling control and MO-treated embryos when collecting embryos for staining or for RNA analyses.

RNA in situ hybridization and immunocytochemistry {#s4c}
-------------------------------------------------

RNA in situ hybridizations were performed as previously described ([@b23]; [@b39]). The following cDNA probes were used: *prdm1a* ([@b16]); *krox-20* (*egr2b*-Zebrafish Information Network) ([@b4]; [@b27]); *mylpfa* (formerly *mylz2*) ([@b50]); *myhz1.3* (formerly *fmyhcX*) ([@b43]); *smyhc1* ([@b5]); *myog* ([@b46]); *atp2a1* ([@b23]); *srl* ([@b23]). Following staining, embryo heads were genotyped for *prdm1a* as above.

Whole-embryo immunostaining was performed with anti-pan zebrafish Pbx, 1:500 ([@b29]) as previously described ([@b23]). For DAPI staining, DAPI was included in the secondary antibody incubation step at a dilution of 1:2000.

Embryos were photographed using a Zeiss Stemi SV6 and Nikon CoolPix 4500 digital camera or imaged using a Zeiss Pascal confocal microscope or Leica TCS SP5 confocal microscope. Images were assembled using Adobe Photoshop.

RNA genotyping of single embryos and quantitative (q) RT-PCR {#s4d}
------------------------------------------------------------

Embryos were collected from *prdm1a+/−* parents and injected with either control MO (*pbx2*-MO3 mismatch or Standard Control MO) or *pbx2/4*-MO combination. Total RNA from individual embryos was isolated using the RNAqueous Micro Kit (Ambion). RNA samples were genotyped for *prdm1a* from residual DNA. We then pooled RNA samples from about 10 equivalent-genotype embryos for four classes: *control*-MO;*prdm1+/+*; *control*-MO;*prdm1−/−*; *pbx2/4*-MO;*prdm1+/+*; and *pbx2/4*-MO;*prdm1−/−*. These pooled samples were then further cleaned and concentrated using the RNeasy MinElute Kit (Qiagen). 100 ng of pooled RNA samples plus random hexamers were used in a reverse-transcriptase reaction with SuperScriptII Reverse Transcriptase (Invitrogen). Real-time PCRs were performed using SYBR Green (Bio-Rad) and an Applied Biosystems 7900HT System according to the manufacturer\'s instructions. The relative expression levels were normalized to those of *ornithine decarboxylase* (*odc1*) ([@b23]). For primers, see [Table 1](#t01){ref-type="table"}.

RNA-seq library preparation and sequencing {#s4e}
------------------------------------------

Total RNA samples were genotyped and pooled as above for *control*-MO;*prdm1+/+*; *control*-MO;*prdm1−/−*; *pbx2/4*-MO;*prdm1+/+*; and *pbx2/4*-MO;*prdm1−/−* embryos at the 10 somite (s) stage from three independent sets of egg collections/injections. An additional set of embryos from each set of injections were processed for in situ hybridization to confirm somite staging as well as loss of *krox-20* expression in *pbx2/4*-MO embryos (see [Fig. 2A](#f02){ref-type="fig"} for example). Library preparation and sequencing was carried out by the FHCRC Genomics Shared Resource. Sequencing libraries were prepared from total RNA using the TruSeq RNA Sample Prep Kit (Illumina) according to the manufacturer\'s instructions. Library size distributions were validated using an Agilent 2100 Bioanalyzer. Additional library quality control, blending of pooled indexed libraries, and cluster optimization were performed using the QPCR NGS Library Quantization Kit (Agilent Technologies). RNA-seq libraries were pooled (4-plex) and clustered onto a flow cell lane using an Illumina cBot. Sequencing occurred on an Illumina HiSeq 2000 using a single-read, 100 base read length (SR100) sequencing strategy.

RNA-seq data processing and analysis {#s4f}
------------------------------------

Image analysis and base calling were performed with Illumina\'s Real Time Analysis v1.12 software. Files were demultiplexed of indexed reads and generated in FASTQ format using Illumina\'s CASAVA v1.8. software. Reads were removed that did not pass Illumina\'s base call quality threshold. Reads were aligned to zebrafish genome build Zv9 release 63, using TopHat 1.4 ([@b41]). SAMtools v0.1.18 ([@b19]) was used to sort and index the TopHat alignments such that they could be visualized in the Integrative Genomics Viewer ([@b31]). The gene expression profiles of *control*-MO;*prdm1+/+* versus *control*-MO;*prdm1−/−*; *pbx2/4*-MO;*prdm1+/+*; and *pbx2/4*-MO;*prdm1−/−* embryos were compared using the Bioconductor package edgeR ([@b30]). To include reads that mapped to multiple homologs in the zebrafish genome, including the myosin heavy chain genes, reads with multiple hits on the genome were kept, and each hit received a fractional count equal to one over the number of hits. Venn diagrams were generated using BioVenn ([@b18]). Data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE45532.
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